Nektar Therapeutics (NKTR) Short-term Investments (2010 - 2026)

Nektar Therapeutics' Short-term Investments history runs 17 years deep, the most recent figure standing at $419.0 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 133.13% year-over-year to $419.0 million; the TTM figure through Mar 2026 stood at $419.0 million (up 133.13% YoY), while the FY2025 annual figure was $230.6 million, up 9.32% from the prior year.
• Short-term Investments for Q1 2026 stood at $419.0 million, up from $230.6 million in the prior quarter.
• The five-year high for Short-term Investments was $599.0 million in Q1 2022, with the low at $132.9 million in Q2 2025.
• The 5-year median for Short-term Investments is $268.3 million (2023), against an average of $318.4 million.
• The sharpest annual moves came in 2022 and 2026: Short-term Investments slumped 49.18% in 2022, then soared 133.13% in 2026.
• Nektar Therapeutics' Short-term Investments stood at $416.8 million in 2022, then tumbled by 35.61% to $268.3 million in 2023, then decreased by 21.38% to $211.0 million in 2024, then gained by 9.32% to $230.6 million in 2025, then jumped by 81.68% to $419.0 million in 2026.
• Business Quant data shows NKTR's Short-term Investments at $419.0 million in Q1 2026, $230.6 million in Q4 2025, and $229.2 million in Q3 2025.